Translational Development Acquisition Corp.
NASDAQ:TDACShell Companies
-$0.01 today
- Market cap
- $267.99M
- Beta
- 0.01
- P/E (TTM)
- 29.8
- EPS (TTM)
- $0.36
Volume 0.47M
Average 0.10M
TDAC Free Cash Flow
Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.
Translational Development Acquisition Corp.NASDAQ: TDAC
Free Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Free cash flow growth accelerates
Q1 FY2026 free cash flow of $305.16K (cash outflow) rose 31.8% year over year, ahead of the -37.0% change in trailing-twelve-month free cash flow. Sequentially, it rose 160.0% from the prior quarter. Over 3 fiscal years it compounded at +1512.9% a year.
Context
- Free cash flow grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +31.8% holds above the trailing-twelve-month pace of -37.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Free Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (608.39K) USD
- Year-over-year change
- +28.5%
| Period | Period end | Free Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (608.39K) | +28.5% |
| FY2024 | 2024-12-31 | (851.45K) | -417275.5% |
| FY2023 | 2023-12-31 | (204) | -40.7% |
| FY2022 | 2022-12-31 | (145) | — |
Free Cash Flow vs competitors
How TDAC compares with its peers on the latest reported figures
- TDAC's LTM Mar 2026 free cash flow of $681.97K is the 4th largest of the 7 companies compared; the peer median is $656.65K.
- Its year-over-year change of -37.0% is the 4th highest of 5, against a peer median of +79.5%.
- Over three fiscal years its annual growth of +1512.9% compares with a peer median of -14.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| FY2022 | $890.19K | +8153.2% | — | — | |
| LTM Mar 2026 | $809.12K | +165.9% | -14.2% | — | |
MACIMelar Acquisition Corp. I | LTM Mar 2026 | $681.99K | -6.9% | — | — |
| LTM Mar 2026 | $681.97K | -37.0% | +1512.9% | — | |
NTWONewbury Street II Acquisition Corp | LTM Mar 2026 | $631.31K | — | — | — |
| FY2025 | $600.84K | — | -15.2% | — | |
| LTM Mar 2026 | $1 | -100.0% | — | — | |
| Peer median (excluding TDAC) | $656.65K | +79.5% | -14.7% | — | |
Competitors are the stored peer set for TDAC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Net Income | (71) | (485.55K) | (71.01K) | 6.36M |
| Depreciation & Amortization | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Change in Working Capital | (75) | 3.01K | (659.81K) | 336.15K |
| Accounts Receivables | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | (449.75K) | 29.01K |
| Other Working Capital | (75) | 3.01K | (210.06K) | 307.14K |
| Other Non-Cash Items | (97.02K) | 482.34K | (120.63K) | (7.31M) |
| Operating Cash Flow | (145) | (204) | (851.45K) | (608.39K) |
| Capital Expenditures | 4 | 0 | (4) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (174.23M) | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | (174.23M) | 0 |
| Debt Repayment | 225K | 0 | (393.46K) | 200K |
| Common Stock Issued | (125.61K) | 0 | 169.05M | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | (125.35K) | 0 |
| Other Financing Activities | 0 | 0 | 6.98M | 0 |
| Financing Cash Flow | 99.39K | 0 | 175.51M | 200K |
| Effect of Forex Changes | 0 | 0 | 0 | 0 |
| Net Change in Cash | 2.23K | (204) | 436.15K | (408.39K) |
| Free Cash Flow | (145) | (204) | (851.45K) | (608.39K) |
Translational Development Acquisition Corp.
NASDAQ:TDAC
Intrinsic Alpha fair value
Locked
Current Price
$10.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.